Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development
July 21, 2015 at 14:00 PM EDT
Bristol-Myers Squibb Company (NYSE: BMY) today announced additional Phase IIa proof-of-concept data for BMS-955176, a novel ...